Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval.

In the paper

“Side effects could be largely mitigated in both preclinical and clinical studies by using polymeric micelle formulations.”

What the sources say

• ?Not checked — no full text of the sourcecites [11] source
• Disputed

  The Abstract (page unavailable) says the micellar formulation SP1049C had similar toxicology to conventional doxorubicin in mice and rats. The Toxicity section (page unavailable) says its overall adverse-event spectrum in patients was also similar to conventional doxorubicin, rather than largely mitigated. (LLM, conf=0.90)

  Checked by a reasoning model — may be wrong.

  cites [17] sourceExperimental — accuracy not yet measured

In the paper

“The clinically approved doxorubicin liposome formulation, DOXIL®, has also shown the ability to induce the ABC phenomenon in human patients mainly due to the development of anti-PEG antibodies in the body after the initial treatment of DOXIL® [82].”

What the sources say

• Disputed

  The Introduction says Doxil hypersensitivity reactions occur mostly at first exposure, without prior sensitization. The Patients and Complement activation by Doxil in vivo sections study first-time recipients and report complement activation after infusion, not accelerated blood clearance (ABC) after an initial treatment. The cited paper therefore describes a different reaction and does not support anti-PEG antibodies as the claimed mechanism. (LLM, conf=0.87)

  Checked by a reasoning model — may be wrong.

  cites [82] sourceExperimental — accuracy not yet measured

In the paper

“Some other paclitaxel polymeric micelle formulations, such NK105, were also reported to have lower toxicity in clinical trials compared to Taxol® [238].”

What the sources say

• Disputed

  The Discussion (page not available in our copy) says NK105’s observed toxicities were similar to those expected for conventional paclitaxel, not lower. It says whether NK105 causes less peripheral neuropathy requires future trials; the lower-toxicity finding it mentions came from animal experiments, not this clinical trial. (LLM, conf=0.88)

  Checked by a reasoning model — may be wrong.

  cites [238] sourceExperimental — accuracy not yet measured

In the paper

“It can be optimized by increasing mixing times to obtain drug-containing polymeric micelles and block copolymer coated drug nanoparticles with desired size, coating, and other characteristics [269].”

What the sources say

• Disputed

  The Principles section (page unavailable) says the opposite of the claimed optimization: longer mixing times promote particle growth, so flash nanoprecipitation requires a higher mixing rate and shorter mixing time. The MIVM section (page unavailable) does discuss producing drug polymeric micelles, but that does not support increasing mixing times to obtain the desired particles. (LLM, conf=0.90)

  Checked by a reasoning model — may be wrong.

  cites [269] sourceExperimental — accuracy not yet measured

In the paper

“The Luxenhofer group has shown that hydrophilic blocks can play substantial role in drug polymer interaction especially in highly drug loaded polymeric micelles [30].”

What the sources say

• Partly supported

  The Introduction (page unavailable) describes hydrophilic pMeOx blocks in both micelles and reports high curcumin loading, while the Results and Discussion (page unavailable) examines drug–polymer interactions in the micellar core. The paper does not show that the hydrophilic blocks play a substantial role in those interactions, especially at high drug loading. (LLM, conf=0.85)

  cites [30] sourceExperimental — accuracy not yet measured

In the paper

“Other hydrophilic polymers such as poly[N-(2-hydroxypropyl) methacrylamide] (HPMA), poly(vinylpyrrolidone) (PVP), poly(N,N-dimethylacrylamide) (PDMA) and poly(N-acryloyl morpholine) did not induce ABC, indicating these polymers may have superior anti-fouling properties.”

What the sources say

• Supported

  The Results section (“Accelerated Blood Clearance in Rats”) reports that rats given an initial dose of liposomes coated with HPMA, PVP, PDMA, or PAcM showed no ABC effect after a second dose seven days later. The Abstract identifies PAcM as poly(N-acryloyl morpholine). (LLM, conf=0.94)

  cites [83] source

In the paper

“Poly(2-oxazoline) (POx)-based block copolymers recently gained a lot of interest as novel biomaterials due to their biocompatibility and chemical versatility [44, 45].”

What the sources say

• Supported

  The Background (Section 2; page not provided) describes POx as a versatile platform for biomaterials, and Section 2.1 describes readily synthesized POx block copolymers. Section 2.3 reports generally low in vitro cytotoxicity while noting that clinical safety needs further study. Together, these passages support the claim as a statement about interest in POx-based block copolymers, not proven clinical safety. (LLM, conf=0.90)

  cites [44] source
• ?Not checked — no full text of the sourcecites [45] source

In the paper

“These mucus penetrating properties are conferred by the polarity of the molecule and overall net neutral charge which has been shown to enhance the penetration of nanomedicines through mucosal barriers [72, 73].”

What the sources say

• ?Not checked — no full text of the sourcecites [72] source
• Partly supported

  The Background says the authors hypothesized that PEG’s hydrophilic, uncharged nature could prevent mucoadhesion, and reports rapid diffusion of densely PEG-coated nanoparticles through mucus. But it qualifies this effect: sufficient coating density is needed, and the proposed mechanism is a hypothesis rather than an established consequence of polarity and charge alone. No page number is available in our copy. (LLM, conf=0.87)

  cites [73] sourceExperimental — accuracy not yet measured

In the paper

“Otherwise, polymeric micelles could be readily cleared from the body by plasma protein adsorption and/or complement activation leading to the removal of the entire micelle along with the drug within its core by the reticuloendothelial system (RES) [31, 32].”

What the sources say

• ?Not checked — no full text of the sourcecites [31] source
• Partly supported

  The Introduction (page not available) says coating reduces nanoparticle interactions with plasma proteins and macrophages, resulting in less RES uptake. The Discussion (page not available) suggests complement may contribute to macrophage uptake, but the paper does not establish that lack of anti-fouling design readily clears whole drug-loaded micelles and their cargo. (LLM, conf=0.83)

  cites [32] sourceExperimental — accuracy not yet measured

In the paper

“They found that both PEG hydrophilic shells and PMeOx hydrophilic shells on liposomes induced the ABC phenomenon in rats after the initial dose of the same liposomes.”

What the sources say

• Supported

  The Results section (“Accelerated Blood Clearance in Rats”) reports that rats received an initial dose of polymer-coated liposomes followed seven days later by liposomes with the same polymer. Both PEG- and PMOX-coated liposomes showed accelerated clearance on the second dose. The effect occurred after, not during, the initial dose. (LLM, conf=0.93)

  cites [83] source

In the paper

“Additional molecular interactions existing in the core, such as hydrogen bonding and pi-pi interactions, are no less significant as they can strengthen the molecular interactions between the polymer and the drug in the core [28, 39].”

What the sources say

• Supported

  The Discussion (page not specified) says the side chains may form strong pi-pi stacking interactions with drug molecules and enable hydrogen bonding with selected drugs. It also describes additional interactions in the micelle core as a possible explanation for differences in drug solubilization. This supports the claim that such interactions can strengthen polymer–drug interactions. (LLM, conf=0.91)

  cites [28] source
• Supported

  Section 3.1.3 (Hydrogen Bonding; page not provided) describes hydrogen bonding between doxorubicin and polymer groups and reports enhanced drug retention. Sections 2.1.1 and 3.1.1 (π-π Stacking; pages not provided) describe stacking involving loaded doxorubicin and polymer-bound doxorubicin, contributing to micelle stability and drug retention. Together, these support the claimed role of both interactions in the micellar core. (LLM, conf=0.92)

  cites [39] source

In the paper

“It is well studied that systemic exposure to PEG may cause ABC in humans [78].”

What the sources say

• Supported

  The “Anti-PEG immunity in humans” section reports that anti-PEG antibodies formed after an intravenous PEG-uricase infusion and were associated with rapid drug clearance. This supports the hedged claim that systemic exposure to a PEGylated therapeutic may lead to accelerated clearance in humans; the reported effect concerns PEGylated drugs, not free PEG. (LLM, conf=0.88)

  cites [78] source

In the paper

“This study, along with others, indicate that PMeOx may actually have superior anti-fouling properties to that of PEG [89].”

What the sources say

• Supported

  In Results and discussion §3.3, the paper reports that PMeOx-coated particles had less cellular uptake than PEG-coated particles and concludes that POx coatings prevent nanoparticle–cell interactions more efficiently. The Conclusions (§4) state that PMeOx showed improved screening capability compared with PEG. These findings support the citing sentence’s hedged claim about superior anti-fouling properties in the viral-nanoparticle system studied. (LLM, conf=0.88)

  cites [89] source

In the paper

“It was found that the methoxy group of the mPEG-protein contributed to a significantly higher immune response than that of hydroxy group of HO-PEG.”

What the sources say

• Partly supported

  The Discussion (page unavailable) says methoxy groups contribute significantly to anti-PEG antibody titers in immunized rabbits. The Results (page unavailable) also report higher relative titers when antibodies from mPEG-immunized rabbits were measured against mPEG rather than HO-PEG antigens. But the paper treats the broader claim that HO-PEG conjugates provoke weaker immune responses as a hypothesis, not an established overall finding. (LLM, conf=0.83)

  cites [81] sourceExperimental — accuracy not yet measured

In the paper

“Examples of polyesters for solubilizing hydrophobic drugs are PCL, PDLLA and PLGA [106–108].”

What the sources say

• Supported

  The PLGA portion of the grouped citation is supported. Section 3.1 describes hydrophobic drugs such as steroids being solubilized or dispersed in a polymer solution during preparation of PLGA carriers. This paper is not needed to establish the PCL or PDLLA examples, which have other citations in the group. (LLM, conf=0.86)

  cites [106] source
• ?Not checked — no full text of the sourcecites [107] source
• Partly supported

  The sustained- and controlled-release section (page unavailable) says hydrophobic drugs can be dissolved or dispersed in a PLA matrix. The References section mentions poly(D,L-lactic acid) in a study of hydrophobic-drug release, but it does not establish PCL or PLGA as polyesters used to solubilize such drugs. The cited paper therefore supports the claim only for the PLA-related example, not the full three-polyester list. (LLM, conf=0.84)

  cites [108] sourceExperimental — accuracy not yet measured

In the paper

“More recently, a variety of POx and poly(2-oxazine) (POzi) based polymers such as poly(2-n-butyl-2-oxazoline) (PBuOx) and poly(2-n-butyl-2-oxazine) (PBuOzi) have gained much attention due to their high loading for physically encapsulating drugs [45, 63, 65].”

What the sources say

• ?Not checked — no full text of the sourcecites [45] source
• ?Not checked — no full text of the sourcecites [63] source
• Partly supported

  The paper’s main text (page unavailable) reports that a poly(2-oxazoline)/poly(2-oxazine) triblock copolymer physically encapsulates more than 50 wt.% curcumin, supporting the general point about high drug loading. Its studied oxazine block is pPrOzi, however; the passages do not establish high loading for the named examples PBuOx or PBuOzi. (LLM, conf=0.85)

  cites [65] sourceExperimental — accuracy not yet measured

In the paper

“One major advantage of using polyesters is their biodegradability [60].”

What the sources say

• Partly supported

  The introduction describes PGA, PLA, and PLGA polyesters as materials used for biodegradable sutures, and Section 2.2.1 calls aliphatic polyesters extensively studied degradable polymers. The review also distinguishes degradability by hydrolysis from biodegradability in the strict IUPAC sense, noting that evidence for biological breakdown of many ester-based drug-delivery polymers is limited or conflicting. The claim captures their useful degradability but omits that qualification. (LLM, conf=0.84)

  cites [60] sourceExperimental — accuracy not yet measured

In the paper

“Interestingly, some studies revealed that dextran as a shielding agent for nanoparticles displayed anti-fouling effects and prolonged circulation in animal models [96, 97].”

What the sources say

• Partly supported

  The Abstract and Discussion report that crosslinked dextran hydrogel reduced macrophage recognition and prolonged circulation of iron oxide nanoparticles in mice. The claim omits the crosslinking condition: the paper describes unmodified dextran-coated particles as short-circulating. Its Discussion also says the hydrogel still allowed many plasma proteins to bind, so its antifouling effect should not be read as general resistance to protein adsorption. (LLM, conf=0.87)

  cites [96] sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [97] source

In the paper

“Among hydrophilic poly(amino acid)s, poly(sarcosine) has shown effective anti-fouling properties in recent studies [49, 94, 95].”

What the sources say

• ?Not checked — no full text of the sourcecites [49] source
• ?Not checked — no full text of the sourcecites [94] source
• Supported

  Section 4 (Conclusions) states that polysarcosine was an excellent antifouling polymer when surface-grafted as a brush. It reports resistance to protein adsorption and cell attachment, supporting the citing sentence’s broad claim. (LLM, conf=0.95)

  cites [95] source

In the paper

“The clinically approved polymeric micelle formulation of paclitaxel Genexol® PM formulation exploits mPEG-b-PDLLA to solubilize paclitaxel and is discussed in greater detail in Section 5.3 [110].”

What the sources say

• Supported

  The Introduction identifies Genexol-PM as a polymeric micelle formulation of paclitaxel, states that it contains mPEG-PDLLA and paclitaxel, and says it is approved in South Korea. This supports the citing sentence’s description of the polymeric micelle used to formulate paclitaxel; the approval is specifically in South Korea. (LLM, conf=0.92)

  cites [110] source

In the paper

“A notable property of select Pluronic® block copolymers to act as biological response modifiers to sensitize multidrug resistant (MDR) and cancer stem cells with respect to anticancer chemotherapeutics was widely reported and reviewed from mechanistic and translational points of view [25, 104].”

What the sources say

• Partly supported

  The section “Pluronic Block Copolymers as Biological Response Modifiers” (page unavailable) says select Pluronics sensitize multidrug-resistant cancer cells, and the paper describes effects relevant to anticancer treatment. Our copy does not report sensitization of cancer stem cells; a search for “stem cells” found no supporting passage. (LLM, conf=0.88)

  cites [25] sourceExperimental — accuracy not yet measured
• Supported

  The Abstract says Pluronics sensitize MDR cancer cells to doxorubicin, paclitaxel and other drugs, and can deplete drug-resistant cancer stem cells. The Conclusions add that combining Pluronic with doxorubicin effectively depletes a tumorigenic cell subpopulation. The supplied passages do not give page numbers. (LLM, conf=0.93)

  cites [104] source

In the paper

“They showed that PMeOx had superior muco-penetrating properties, as measured by the diffusion coefficient in gastric mucus, compared to silica nanoparticles.”

What the sources say

• Supported

  Section 3.4 reports that PMOZ-coated silica nanoparticles had significantly higher diffusion coefficients than unfunctionalised thiolated silica nanoparticles in gastric mucin dispersions at both tested temperatures. This supports the claimed comparison, with the qualification that the diffusion-coefficient measurement used a gastric mucin dispersion. (LLM, conf=0.92)

  cites [91] source

In the paper

“POx hydrophilic blocks have also demonstrated improved mucus penetrating properties which could be useful in the oral delivery of polymer micelles [91].”

What the sources say

• Partly supported

  The Results (§3.4) and Conclusions (§4) show that more hydrophilic POx coatings improved the diffusion and mucosal penetration of silica nanoparticles; the Introduction (§1) discusses potential oral drug delivery. The paper did not test polymer micelles, so the proposed application to their oral delivery is an extrapolation. (LLM, conf=0.84)

  cites [91] sourceExperimental — accuracy not yet measured

In the paper

“Prior to adding the ring structure, the polymer was unable to form micelles in aqueous solution.”

What the sources say

• Partly supported

  The Results section (“Self-assembly of PMeOx-PcBOx copolymer”; page unavailable) reports that the triazine-containing polymer formed particles in aqueous media. It also reports no proton correlations in a test of the precursor, PMeOx-PMestOx, but does not establish that the precursor was unable to form micelles. The claim’s assertion about the polymer before modification is therefore unsupported. (LLM, conf=0.83)

  cites [28] sourceExperimental — accuracy not yet measured

In the paper

“Interestingly, it was recently reported that such high loading capacity of poorly soluble drugs in POx micelle was due to the structure of both the hydrophilic and hydrophobic blocks in POx triblock copolymers [119].”

What the sources say

• Supported

  The Introduction says drug-loading relationships had been established for the hydrophobic block and that this study examines the hydrophilic block. The Synthesis and Drug Formulation section reports that changing the hydrophilic block substantially reduced loading while drug-specific differences associated with the hydrophobic block remained. The conclusion likewise says both the hydrophobic block and interactions with the hydrophilic corona matter for the unusually high loading. (LLM, conf=0.91)

  cites [119] source

In the paper

“Such properties allow to employ PBAE as a core-forming segment for solubilizing poorly soluble drugs in PEG-b-PBAE polymeric micelles at physiological pH 7.4 [139].”

What the sources say

• Supported

  Section 3.3 (p. 8) identifies PBAE as part of the micelle core and reports that the micelles remain stable at pH 7.4. Sections 2.3 (p. 4) and 3.3 (p. 8) describe loading thioridazine into the micelles, removing insoluble drug, and achieving over 85% encapsulation efficiency. Together, these passages support the claimed use of PBAE as a core-forming segment for carrying a poorly soluble drug at physiological pH. (LLM, conf=0.88)

  cites [139] source

In the paper

“Several pH-sensitive polymers have been employed in polymeric micelle formulations including polycations such as poly(histidine) [131], poly(4-vinylpyridine) [132], poly(N,N-dimethylaminoethylmethacrylate) [133], poly(β-amino ester) (PBAE) [134], and polyanions, such as poly(acrylic acid) [135], poly(methacrylic acid) (PMAA) [136], and poly(sulfonamides) [137].”

What the sources say

• Supported

  The Introduction identifies poly(l-histidine) as a pH-sensitive polymer and describes its use in micelles. Citation [131] is attached specifically to poly(histidine), not to the other polymers in the sentence. (LLM, conf=0.94)

  cites [131] source
• ?Not checked — no full text of the sourcecites [132] source
• ?Not checked — no full text of the sourcecites [133] source

In the paper

“We have screened potential hydrophobic drug candidates and found that many hydrophobic drugs can be efficiently solubilized in these POx systems with extremely high drug loading (sometimes approaching or even exceeding 50% by weight drug loading) [116].”

What the sources say

• Partly supported

  The Results (Virtual screening of DrugBank and experimental evaluation) report efficient POx solubilization for several poorly soluble drugs, including podophyllotoxin at 43.2% loading capacity. The Results (Cheminformatics analysis) report docetaxel loading capacity of 47.4%, supporting the claim that loading can approach 50% by weight. The passages do not establish loading exceeding 50%, and the Introduction cautions that POx micelles do not solubilize every poorly soluble drug equally well. (LLM, conf=0.85)

  cites [116] sourceExperimental — accuracy not yet measured

In the paper

“Triblock A-B-A copolymers of POx consisting of hydrophobic PBuOx block with two flanking hydrophilic PMeOx blocks, PMeOx-b-PBuOx-b-PMeOx, have shown unprecedentedly high loading for many poorly soluble drugs [22, 45, 113, 114].”

What the sources say

• ?Not checked — no full text of the sourcecites [22] source
• ?Not checked — no full text of the sourcecites [45] source
• Supported

  The Abstract describes the PMeOx-b-PBuOx-b-PMeOx triblock structure and states that its micelle core enables unprecedentedly high loading for many hydrophobic polar compounds. The Results section also reports high loading of vismodegib in micelles made from this polymer. (LLM, conf=0.93)

  cites [113] source
• Partly supported

  The Abstract identifies the P(MeOx-b-BuOx-b-MeOx) triblock and reports nearly 45 wt% paclitaxel loading. The Results and Discussion report over 50 wt% combined loading of etoposide and a cisplatin prodrug. These passages support very high loading for the drugs discussed, but do not establish it for “many poorly soluble drugs.” (LLM, conf=0.82)

  cites [114] sourceExperimental — accuracy not yet measured

In the paper

“This polymer structure conferred some unique solubilization characteristics likely due increased modalities of drug-polymer interaction, such as hydrogen bonding and pi-pi stacking.”

What the sources say

• Supported

  The Discussion describes distinct drug-solubilization preferences for the triazine-containing polymer and proposes pi-pi stacking and hydrogen bonding as interactions that may explain them. The Introduction likewise says the polymer was designed to use both interactions to help solubilize otherwise incompatible molecules. The citing sentence preserves the paper’s uncertainty about the mechanism. (LLM, conf=0.93)

  cites [28] source

In the paper

“A similar polymeric micelle formulation where CDDP was coordinated with PEG-b-P(Glu) [153] evolved into a clinically evaluated polymeric micelle drug, NC-6004 which is described below in Section 5.3.”

What the sources say

• Supported

  The Results section identifies NC-6004 as a cisplatin-incorporating micelle made from PEG-P(Glu) and describes the coordinate complex between CDDP and P(Glu). The citation is attached to that formulation description; the later characterization of NC-6004 as clinically evaluated is not specifically attributed to this source. (LLM, conf=0.91)

  cites [153] source

In the paper

“In acidic solution, the protonation of carboxylic acid moieties on PMAA accelerated the release of doxorubicin.”

What the sources say

• Supported

  Section 3.3 reports significantly faster doxorubicin release at pH 5.5 than at pH 7.4 and attributes the acceleration to protonation of carboxylic groups on the micelle's PMA chains. The abstract likewise describes accelerated release in an acidic environment due to that protonation. (LLM, conf=0.93)

  cites [170] source

In the paper

“Successful targeted delivery of these drug-loaded micelles to the tumors using tumor-specific ligands attached to the micelle outer PEG chains were also described [179–181].”

What the sources say

• ?Not checked — no full text of the sourcecites [179] source
• Partly supported

  The Results (§3.1) describe core-cross-linked, cisplatin-loaded nanogels with an LHRH ligand attached through a PEG linker; the Discussion (§4) reports enhanced tumor accumulation with LHRH targeting. The paper calls these carriers nanogels and describes attachment to the nanogel surface, not specifically to outer PEG chains of micelles. (LLM, conf=0.84)

  cites [180] sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [181] source

In the paper

“In subsequent studies, a different type of “conjugates” was developed using PEG-b-P(Asp) and PEG-b-P(Glu) – which can form a coordination complex with drugs containing transition metal complexes such as cis-dichlorodiammineplatinum(II) (cisplatin, CDDP), dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt) and cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II) (oxaliplatin) [151].”

What the sources say

• Partly supported

  The micelle-delivery sections and Figure 4 describe coordination complexes of PEG-PAsp or PEG-PGlu with cisplatin and DACHPt. The paper mentions oxaliplatin as a free-drug comparator, not as a drug shown to form one of these polymer complexes. Page numbers are unavailable in our copy. (LLM, conf=0.89)

  cites [151] sourceExperimental — accuracy not yet measured

In the paper

“Notable examples of these studies include loading of the core of the core-crosslinked micelles with CDDP, DACHPt and other anti-cancer drugs and multiple drug combinations that then were used to treat cancer in animal models [176–178].”

What the sources say

• ?Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  cites [176]
• ?Not checked — no full text of the sourcecites [177] source
• Partly supported

  The Methods (Animal studies; no page number in our copy) describe treating mice with cross-linked nanogels carrying CDDP, PTX, or both. The Preparation and characterization section says the nanogels were made by cross-linking micelles, but it specifies cross-linking of the polyion chains, not the micelle core. Our copy does not report DACHPt or animal treatment with other drug combinations. (LLM, conf=0.86)

  cites [178] sourceExperimental — accuracy not yet measured

In the paper

“After removal of the divalent cations doxorubicin was incorporated into the core of such micelles via electrostatic and hydrophobic interactions, and the micelle exhibited high loading of the drug up to 50% wt/wt.”

What the sources say

• Partly supported

  The Methods (§2.2) say the divalent metal ions were removed before DOX loading, and the Results (§3.2) report up to 50% (w/w) loading at pH 7.0. The paper supports electrostatic binding, but describes hydrophobic entrapment in these cross-linked micelles as a possibility it cannot exclude, rather than an established mechanism. Page numbers were not available in our copy. (LLM, conf=0.86)

  cites [170] sourceExperimental — accuracy not yet measured

In the paper

“For the drug containing micelles, the molecular interactions between the solubilized drug and the micelle are also important parameters that can affect not only the stability of the micelle but also its size and morphology, thereby strongly influencing the biological performance of the polymeric micelles as drug delivery vehicles [114, 115].”

What the sources say

• Supported

  The Results (page unavailable) link drug composition and interactions with micelle size, shape, and stability. The Discussion (page unavailable) attributes the worm-like morphology to specific drug–polymer interactions and links morphology and drug retention to pharmacokinetics and therapeutic efficacy. Together, these passages support the claim as a general paraphrase of the paper’s findings. (LLM, conf=0.88)

  cites [114] source
• Supported

  The Discussion (page not specified) says incorporated drugs can affect micelle stability, size, and morphology. The Conclusion (page not specified) links micelle morphology and size to circulation, endocytosis, anticancer activity, and tumor delivery, supporting the claim about biological performance. (LLM, conf=0.88)

  cites [115] source

In the paper

“Recent studies on the experimental analysis of polymeric micelles have shown that the drug-polymer compatibility was achieved via more complex molecular mechanisms of interaction than simple hydrophobic interactions [63, 65, 115].”

What the sources say

• ?Not checked — no full text of the sourcecites [63] source
• Supported

  The paper’s Abstract reports NMR evidence that curcumin interacts with hydrophobic polymer blocks at low loading but increasingly with hydrophilic blocks at higher loading. That loading-dependent interaction supports the cited point that compatibility in these polymeric micelles involves more than simple hydrophobic interactions. (LLM, conf=0.92)

  cites [65] source
• Supported

  The Abstract reports that a more hydrophobic micellar core was not necessarily better for paclitaxel solubilization: increasing core hydrophobicity reduced loading capacity by more than half. It also describes evidence of a polar environment in the better-loading core, supporting the claim that drug–polymer compatibility involves more than simple hydrophobic interactions. Page numbers are unavailable in our copy. (LLM, conf=0.90)

  cites [115] source

In the paper

“Various computational approaches have been proposed to predict the compatibility between the drug and polymer during the encapsulation process, such as using the solubility parameters (SPs) [189], Flory-Huggins interaction parameters [190], Molecular Dynamics (MD) [191], and quantitative structure property relationship (QSPR) [116] (Table 3).”

What the sources say

• ?Not checked — no full text of the sourcecites [189] source
• ?Not checked — no full text of the sourcecites [190] source
• Supported

  The citation to this paper is attached to the molecular dynamics (MD) example, not to the other listed approaches. The Abstract describes MD simulations of Taxol loading in PEG-PCL micelles and says they reveal drug–polymer interactions. (LLM, conf=0.93)

  cites [191] source

In the paper

“MD simulation could also rank order drugs by their loading in polymeric micelles in a good agreement with experimental data.”

What the sources say

• Partly supported

  The Conclusion reports that a model combining MD simulations with docking calculations rank-ordered three drugs by experimentally observed maximum loading. The study tested tyrosine-derived polymeric nanospheres, not polymeric micelles, and does not establish that MD simulation alone produced the ranking. (LLM, conf=0.87)

  cites [206] sourceExperimental — accuracy not yet measured

In the paper

“For example, Costache et al. used a combination of MD and docking calculations which predict preferred orientation of a drug to a polymer for ranking three drugs (curcumin, paclitaxel and vitamin D3) by the energies of binding of with PEG-b-oligo(desaminotyrosyl-tyrosine octyl ester suberate)-b-PEG micelles [206].”

What the sources say

• Supported

  The Methods (Computational Studies; page unavailable) describe MD simulations of the PEG–oligo(DTO-SA)–PEG triblock copolymer and docking of curcumin, paclitaxel, and vitamin D3 into modeled polymer assemblies. The Results and Discussion report their predicted binding geometries and a rank ordering based on calculated binding energies. The Conclusion says the combined model successfully rank-ordered the three drugs against experimentally observed maximum loading. (LLM, conf=0.92)

  cites [206] source

In the paper

“Computational approaches, such as MD, have been extensively utilized to investigate the molecular interactions in polymeric micelles and obtain microscopic insights into the solubilization of small drug molecules in the polymeric micelles [218].”

What the sources say

• Supported

  The Methodology section says most computational studies of drug delivery use MD simulations. The Amphiphilic Copolymers section describes MD studies of drug–polymer interactions and drug solubility in micelle-forming copolymers, providing the microscopic insights the claim describes. Page numbers are unavailable in our copy. (LLM, conf=0.91)

  cites [218] source

In the paper

“This can simulate the process of self-assembly during drug loading in the micelle core [218].”

What the sources say

• Partly supported

  The Amphiphilic Copolymers section (page not provided) reports using MD with docking to examine interactions between hydrophobic drugs and a triblock copolymer. It also describes simulations of drug loading in a micelle core, but those passages do not show that the MD drug–copolymer interaction simulations reproduced self-assembly during loading. (LLM, conf=0.84)

  cites [218] sourceExperimental — accuracy not yet measured

In the paper

“MD approaches are often inappropriate for large data sets commonly encountered in polymeric micelles drug formulation research where the MD simulations could require enormous time, cost, and computational power [218].”

What the sources say

• Partly supported

  The Methodology section (page unavailable) says fully atomistic simulations are too expensive for large systems and that coarse-grained simulations can reduce the computational burden. It does not say that MD approaches generally are inappropriate for large data sets in polymeric micelle formulation research; large systems and large data sets are different claims. (LLM, conf=0.88)

  cites [218] sourceExperimental — accuracy not yet measured

In the paper

“The study demonstrated that the computational QSPR modeling could predict the solubility of water-insoluble drugs with a high accuracy of up to 75 %.”

What the sources say

• Partly supported

  The Results (Cheminformatics analysis; page not provided) report QSPR models predicting drug loading in polymeric micelles, with correct classification rates of 76–85%. The claim captures the modeling approach but describes the endpoint as solubility rather than loading efficiency and capacity, and its 'up to 75%' accuracy does not match the reported range. (LLM, conf=0.88)

  cites [116] sourceExperimental — accuracy not yet measured

In the paper

“Callari et al. showcased the utility of 1D and 2D ssNMR to investigate the correlation between drug loading and size of polymeric micelles [226].”

What the sources say

• Partly supported

  In the section beginning “Polymer micelles are widely applied as nanocarriers for drug” (page not supplied), the paper says 1D and 2D solid-state NMR revealed micelle structure and dynamics. It also reports that low-loading micelles were larger than high-loading micelles, but says their sizes were measured by TEM and dynamic light scattering, not NMR. Thus the cited work supports the use of NMR to compare micelles at different drug loadings, but not the claim that NMR investigated the loading–size relationship. (LLM, conf=0.86)

  cites [226] sourceExperimental — accuracy not yet measured

In the paper

“The erroneous prediction was attributed to the decreased crystallinity of the poly(ε-decalactone) core compared to PCL that was not accounted for in the classic Flory-Huggins approach.”

What the sources say

• Supported

  The Discussion (page not available) says the Flory–Huggins parameter predicted greater drug loading in PCL micelles, but overall loading was higher in PεDL micelles. It attributes that difference to the amorphous PεDL core’s greater volume, consistent with the claim about lower crystallinity. The Conclusions clarify that loading per unit core volume did agree with the Flory–Huggins prediction. (LLM, conf=0.88)

  cites [200] source

In the paper

“This was interpreted as the presence in the core of multiple paclitaxel-rich domains (raspberry nodules) which increased in size from about 2.4 to 3.4 nm as the drug loading increased.”

What the sources say

• Supported

  The Results section (Small-Angle Neutron Scattering; page unavailable) interprets the raspberry-like scattering pattern as PTX-rich domains in the micelles. It reports that the radius of particles embedded in the core increased from 1.2 to 1.7 nm with PTX concentration, equivalent to diameters of 2.4 to 3.4 nm. (LLM, conf=0.94)

  cites [115] source

In the paper

“As the drug was loaded in the micelles at some critical point (>8% paclitaxel loading w/w), the micelles underwent a structural transition from worm-like micelles to small and uniform spherical micelles of about 45–50 nm.”

What the sources say

• Partly supported

  The Results (Aggregate Characterization by AFM and (Cryo-)TEM; page unavailable) report that paclitaxel-loaded micelles became uniform spheres approximately 40–50 nm in diameter by AFM. But the paper does not identify >8 wt % as the threshold for the wormlike-to-spherical switch: the Abstract says small amounts of drug left only spherical morphologies, while the Results (Small-Angle Neutron Scattering; page unavailable) associate >8 wt % with a raspberry-like core structure. (LLM, conf=0.90)

  cites [115] sourceExperimental — accuracy not yet measured

In the paper

“Interestingly, as the curcumin loading increased, the micelle size as measured by dynamic light scattering first decreased and then increased [30].”

What the sources say

• Supported

  The Results and Discussion state that A-pPrOzi-A/curcumin micelles initially decreased in size as curcumin content increased, then increased in size. The Figure 2 caption identifies those size measurements as DLS measurements; the claim accurately paraphrases this result for that micelle formulation. (LLM, conf=0.93)

  cites [30] source

In the paper

“1H-NMR spectroscopy revealed that the latter displayed much greater propensity for interacting with the drug at the lower loadings, which is possibly reducing the colloidal stability of the drug loaded micelles by shrinking the shell.”

What the sources say

• Partly supported

  In the formulations discussion (page unavailable), the authors interpret their ¹H-NMR findings as indicating stronger interaction of pEtOx than pMeOx with curcumin. But their proposed micelle model says there is no major difference at no or very low drug loading; the stronger interaction emerges as loading increases. The claim’s qualification that the greater propensity occurs at lower loadings is therefore not supported as stated. (LLM, conf=0.82)

  cites [46] sourceExperimental — accuracy not yet measured

In the paper

“Due to the micellar structure, these interactions are most likely intermolecular in nature (i.e. not within the same unimer).”

What the sources say

• Supported

  In the Journal of Materials Chemistry B Paper section (page not provided), the source says that, due to micelle formation, the polymer N–H cross-peaks are most likely intermolecular. This supports the citing sentence’s interpretation that the interactions are unlikely to be within the same unimer. (LLM, conf=0.94)

  cites [227] source

In the paper

“To this end, Grune et al. have recently utilized 14N-1H Heteronuclear Multiple Quantum Coherence (HMQC) ssNMR to show the interactions of the PMeOx-b-PBuOx-b-PMeOx triblock copolymer and paclitaxel [227].”

What the sources say

• Supported

  The Introduction identifies the samples as paclitaxel formulations of the pMeOx-b-pBuOx-b-pMeOx triblock copolymer and says the study uses ¹⁴N–¹H HMQC experiments to examine intermolecular contacts. The Discussion interprets the observed cross-peaks as evidence of interactions between paclitaxel and the polymer. (LLM, conf=0.94)

  cites [227] source

In the paper

“At a higher loading of 10:4, additional peaks on the HMQC can be seen which are in the 4.5–8.0 ppm range on the 1H-NMR spectrum.”

What the sources say

• Supported

  The Materials section identifies POL-4-PTX as the 10:4 loading. The Formulations section reports additional HMQC cross-peaks at proton chemical shifts of 4.5 and 8.0 ppm, with weaker signals at 5.6 and 6.4 ppm. Page numbers were not provided in our copy. (LLM, conf=0.94)

  cites [227] source

In the paper

“These peaks indicate that as paclitaxel loading increases, there is an increased interaction between polymer nitrogens and hydrogens involved in the aromatic ring systems and hydrogen bonding of paclitaxel [227].”

What the sources say

• Partly supported

  The Discussion (page not provided) links increasing paclitaxel loading to more polymer-amide nitrogen environments near paclitaxel and identifies possible hydrogen-bonding contacts with its NH and OH groups. The passage about aromatic-proton proximity concerns nitrogens in pure crystalline paclitaxel, not increasing interactions between aromatic hydrogens and polymer nitrogens as loading rises. (LLM, conf=0.86)

  cites [227] sourceExperimental — accuracy not yet measured

In the paper

“At the same level of curcumin absorbance (same curcumin concentration), a higher fluorescence intensity was observed in the POx polymer compared to the POzi polymer.”

What the sources say

• Supported

  The Results and Discussion (page unavailable) state that, at identical curcumin content, absorbance was the same while fluorescence was higher for the POx formulation A-pBuOx-A/CUR than for the POzi formulation A-pPrOzi-A/CUR. The paper specifies that this comparison was observed at polymer/curcumin ratios greater than 10/2. (LLM, conf=0.93)

  cites [30] source

In the paper

“This study suggests a significant role for drug interactions with the hydrophilic block in achieving extremely-high drug loadings.”

What the sources say

• Supported

  The Summary states that interactions between cargo and the hydrophilic corona matter and that ultra-high drug loading in these micelles is apparently possible in part because of the hydrophilic pMeOx block. This supports the citing sentence’s hedged conclusion. (LLM, conf=0.92)

  cites [46] source

In the paper

“Major changes in curcumin peak absorption position were observed when this drug was encapsulated into POx- and POzi-based micelle systems.”

What the sources say

• Supported

  The Results and Discussion report major changes in curcumin absorption upon encapsulation in POx- and POzi-based micelles, including a pronounced shift in peak absorption wavelength as drug loading increased. The paper gives a shift from 432 to 414 nm for the POzi system and states that peak wavelength at a given curcumin concentration was the same for both polymers. No page number is available in our copy. (LLM, conf=0.90)

  cites [30] source

In the paper

“The signal at the negative ppm shift on the nitrogen NMR spectrum continued to increase with increased paclitaxel loading indicating increased interactions with the polymer amides.”

What the sources say

• Supported

  The Discussion assigns the negative-ppm nitrogen signal to polymer amides near paclitaxel molecules and states that it gains intensity relative to the other nitrogen signal as paclitaxel loading increases. The authors present the assignment as a hypothesis, consistent with the citing sentence’s interpretation of the signal. (LLM, conf=0.92)

  cites [227] source

In the paper

“The drug (curcumin) loading was extremely high when more hydrophilic PMeOx was used as the shell forming block in the polymeric micelles.”

What the sources say

• Supported

  Table S6 in the formulation data reports a 54.0% curcumin loading capacity for micelles with pMeOx outer blocks and a pPrOzi core. The microcalorimetry section also describes a drop from 54 wt.% with a pMeOx corona to 28 wt.% with a pEtOx corona, supporting the comparison. (LLM, conf=0.90)

  cites [46] source

In the paper

“Such micelles were also highly stable in solution.”

What the sources say

• Supported

  The Abstract reports that pEtOx reduces the colloidal stability of drug-loaded micelles compared with pMeOx. The Microcalorimetry studies section says micelles enriched in pMeOx remain in solution while the pEtOx-rich formulation precipitates, and that micelles with only pMeOx precipitate at higher drug loading than mixed-shell micelles. This supports the claim for the formulations studied. (LLM, conf=0.87)

  cites [46] source

In the paper

“As the drug loading amount increased, the SANS data suggests that curcumin initially located in the micelle core shifted to the periphery forming an inner “shell” within the micelles.”

What the sources say

• Partly supported

  The Introduction (page not available) reports that, at higher loading, curcumin began to reside in the micelle’s shell-forming block. It does not identify SANS as the evidence or describe curcumin shifting from the core to form an inner shell. (LLM, conf=0.83)

  cites [46] sourceExperimental — accuracy not yet measured

In the paper

“In the absence of the drug, this particular block copolymer formed worm-like micelles as shown in atomic force microscopy and cryo-TEM with an effective hydrodynamic diameter of about 200 nm.”

What the sources say

• Partly supported

  The Results section on AFM and (cryo-)TEM reports that drug-free P2 contained both wormlike and spherical micelles, with the wormlike structures visible by cryo-TEM. It also says AFM could not visualize the drug-free micelles. The DLS Results give the larger aggregates a hydrodynamic radius of 79 ± 25 nm—an approximate diameter of 158 ± 50 nm—but do not identify that measurement specifically as the diameter of the worms. (LLM, conf=0.85)

  cites [115] sourceExperimental — accuracy not yet measured

In the paper

“1H-NMR spectroscopy revealed that the latter displayed much greater propensity for interacting with the drug at the lower loadings, which is possibly reducing the colloidal stability of the drug loaded micelles by shrinking the shell.”

What the sources say

• Partly supported

  The ¹H-NMR discussion reports that pEtOx loses mobility even at low curcumin loading and interacts more strongly with curcumin than pMeOx as loading increases. The paper links pEtOx-corona dehydration to agglomeration, but does not establish shell shrinkage or reduced colloidal stability at the lower loading: its DLS section reports no significant micelle-size differences at 2 g/L curcumin. (LLM, conf=0.80)

  cites [46] sourceExperimental — accuracy not yet measured

In the paper

“At higher loading, there was an increased interaction of the drug with the carbonyl-carbon of the hydrophilic PMeOx blocks.”

What the sources say

• Supported

  The HETCOR discussion (labeled Abstract in our copy; page not supplied) reports additional curcumin–pMeOx contacts at medium loading, including contacts to the carbonyl group. The structural-model discussion says curcumin interacts increasingly with the hydrophilic block as loading rises. (LLM, conf=0.91)

  cites [65] source

In the paper

“At a low 10:2 (weight polymer:weight paclitaxel) loading, all cross peaks occur in the aliphatic region of the 1H-NMR spectrum indicating that primarily interactions between aliphatic hydrogens on the polymer and the nitrogens on the polymer backbone are occurring.”

What the sources say

• Supported

  The Materials section identifies POL-2-PTX as the 10:2 polymer-to-paclitaxel formulation. The Formulations section reports that all its HMQC cross-peaks appear in the aliphatic ¹H region below 2 ppm, and the Discussion says its spectrum is dominated by polymer–polymer contacts. The neat-polymer peak assignments identify proximities between polymer nitrogen and aliphatic side-chain hydrogens. (LLM, conf=0.91)

  cites [227] source

In the paper

“At a low loading, the drug primarily accumulated in the core of the micelle where it interacted with the hydrophobic PPrOzi block via hydrogen bonding between phenolic OH group of curcumin and the amide group in the polymer backbone.”

What the sources say

• Supported

  The structural-model passage (labeled Abstract; no page supplied) says that at the lowest loading, curcumin is mainly in the micellar core and forms hydrogen bonds between its phenolic OH groups and the amide moiety of the hydrophobic block. The paper identifies that block as pPrOzi. (LLM, conf=0.94)

  cites [65] source

In the paper

“This indicates that the added degree of flexibility may play a critical role in the differential solubilization capacity of POzi with regard to curcumin.”

What the sources say

• Partly supported

  The Conclusions (page unavailable) say curcumin retains more flexibility in POzi micelles, probably partly because the polymer is more flexible, and report that those micelles allow much higher drug loading. They do not establish that polymer flexibility plays a critical role in the difference in curcumin solubilization capacity. (LLM, conf=0.78)

  cites [30] sourceExperimental — accuracy not yet measured

In the paper

“Consistent with the NMR study discussed in the previous section, this drug revealed differential localization depending on its loading amount in the micelles.”

What the sources say

• Partly supported

  In the section on pPrOzi micelle formulations (page unavailable), the paper proposes a tentative loading-dependent model: as curcumin loading increases, the pEtOx corona interacts more strongly with the drug. That supports a loading-dependent change in the micelles, but the paper does not report SANS analysis or establish curcumin’s differential localization by that method; its relevant measurements include NMR. (LLM, conf=0.85)

  cites [46] sourceExperimental — accuracy not yet measured

In the paper

“Interestingly, ssNMR analysis of the changes in the chemical shifts and cross-peaks in 2D correlation revealed that the degree of curcumin loading in polymeric micelle affected the localization of the drug in the micelle.”

What the sources say

• Partly supported

  The Abstract reports that chemical shifts and 2D NMR cross-peaks indicate different curcumin–polymer interactions at low and high loading. The Figure 5 structural-model discussion places curcumin mainly in the core at low loading but says its location at the hydrophilic–hydrophobic interface at higher loading is envisaged. Thus, the paper supports a loading-dependent localization model, but 'revealed' presents the proposed location more definitively than the source does; page numbers were not supplied. (LLM, conf=0.82)

  cites [65] sourceExperimental — accuracy not yet measured

In the paper

“The micelles with the mixed PEtOx and PMeOx shell displayed an intermediate result.”

What the sources say

• Supported

  The formulation discussion ranks drug-loading results as A-B-A > A*-B-A > A*-B-A* and identifies A*-B-A micelles as having a mixed pMeOx/pEtOx corona. The mixed-shell formulation therefore falls between the pMeOx-only and pEtOx-only formulations. (LLM, conf=0.88)

  cites [46] source

In the paper

“Schultz et al. reported on the morphological change of micelle structure upon the incorporation of paclitaxel in PMeOx-b-PBuOx-b-PMeOx polymeric micelles [115].”

What the sources say

• Supported

  The Abstract reports a profound morphology change when paclitaxel was incorporated into micelles containing poly(2-methyl-2-oxazoline) outer blocks and a poly(2-n-butyl-2-oxazoline) middle block. The Discussion specifies that paclitaxel caused wormlike micelles to disintegrate and describes structural changes in P[MeOx-b-BuOx-b-MeOx] micelles. (LLM, conf=0.94)

  cites [115] source

In the paper

“They compared micelles with varied drug loading and from ssNMR analysis concluded that as the drug loading increased the chain mobility and swelling in the core and shell of the micelle decreased.”

What the sources say

• Partly supported

  In the main discussion (pp. 8441–8445), solid-state NMR describes the high-loading micelles as rigid and the low-loading micelles as having a mobile outer corona; the low-loading micelles also absorb more water. This supports reduced mobility and hydration with higher loading overall, but the text does not establish that mobility and swelling each decreased in both the core and shell: it describes the low-loading core as rigid too. (LLM, conf=0.78)

  cites [226] sourceExperimental — accuracy not yet measured

In the paper

“Further physicochemical analysis of these paclitaxel loaded polymeric micelles by SANS revealed that the micelle core represents a raspberry-like sphere morphology with a diameter of 4 to 6 nm.”

What the sources say

• Partly supported

  The Results section (Small-Angle Neutron Scattering; page unavailable) reports that SANS measurements found micellar-core spheres with radii of 4–6 nm, not diameters. It also says that formulations with more than 8 wt % paclitaxel were modeled as raspberry-like spheres, supporting the morphology claim only at those drug loadings. (LLM, conf=0.90)

  cites [115] sourceExperimental — accuracy not yet measured

In the paper

“Bioequivalence analysis by statistical analysis (two one-sided t-test) revealed that the Abraxane® and Genexol® PM formulations were bioequivalent in total drug PK parameters.”

What the sources say

• Partly supported

  The Results (page unavailable) say Abraxane and Genexol-PM had no significant differences in total-drug PK parameters in rats and describe their total-drug PK as equivalent. But the Statistics section (page unavailable) specifies Student’s t test or one-way ANOVA with Tukey’s posthoc test, not a two one-sided t-test. The paper also says the products lack bioequivalence testing, so its rat PK comparison does not establish bioequivalence by the claimed analysis. (LLM, conf=0.91)

  cites [247] sourceExperimental — accuracy not yet measured

In the paper

“In a recent study, the authors applied the SITUA method to analyze the PK profiles of several clinically approved nanomedicines and their generic or nanosimilar formulations, some of which lack bioequivalence testing.”

What the sources say

• Supported

  The Abstract (pp. 547–558) says the authors used SITUA to compare the pharmacokinetics of Doxil and a generic liposomal doxorubicin, generic Taxol, Abraxane, and Genexol-PM. It also distinguishes the approved therapeutic-equivalent liposomal products from same-active-ingredient paclitaxel formulations that lack bioequivalence testing. (LLM, conf=0.94)

  cites [247] source

In the paper

“The relative tumor delivery of nanoparticles was ~100-fold greater as assessed by the standard AUCtumor/AUCblood ratio than by %ID in tumor.”

What the sources say

• Supported

  The Results table reports median values of 76.12% for AUCtumor/AUCblood and 0.67% for %ID in tumor—about a 114-fold numerical difference. The Discussion likewise says the metrics yield substantially different absolute values and interpretations; this is a comparison of assessments, not a change in actual delivery. (LLM, conf=0.93)

  cites [244] source

In the paper

“It has also been noted that as polymer concentrations increase, this can inhibit the caveolae mediated endocytosis at least in the case of certain poloxamers with sufficiently long PPO blocks [239].”

What the sources say

• Partly supported

  Section 8.2 reports that Pluronic P85 inhibits caveolae-mediated endocytosis at concentrations above its critical micelle concentration. It identifies P85 as a PEO–PPO block copolymer, but does not establish that a sufficiently long PPO block is the condition for this effect or extend the finding to other poloxamers. (LLM, conf=0.82)

  cites [239] sourceExperimental — accuracy not yet measured

In the paper

“While limited in scope, this study shows that in vitro release can give some insights into the differential affinity between drugs and various polymeric micelle core structures.”

What the sources say

• Supported

  The Results (Solubilization of poorly soluble small molecules; page unavailable) report different in vitro release of paclitaxel from the two micelle formulations, but similar release of bruceantin. The Discussion (page unavailable) links those profiles to different drug-loading mechanisms and block structures, supporting the modest claim that release data can offer insights into drug–micelle interactions. (LLM, conf=0.86)

  cites [28] source

In the paper

“However, the generic Taxol formulation did show some marked differences in key PK parameters when compared to Abraxane® and Genexol® PM.”

What the sources say

• Supported

  The Results report significantly lower clearance and distribution-volume parameters for generic Taxol than for Abraxane and Genexol-PM. The Discussion likewise describes marked differences between the Taxol group and the other two groups in the rat pharmacokinetic study. (LLM, conf=0.95)

  cites [247] source

In the paper

“A recent reanalysis by Price et al., based on the same dataset, has cast major doubt on the validity of Wilhelm et al. conclusions [244].”

What the sources say

• Supported

  The Introduction says Price et al. reanalyzed source data from the 117 studies evaluated by Wilhelm et al. and found that Wilhelm’s metric correlated poorly with established pharmacokinetic measures. It explicitly says those findings suggest Wilhelm et al.’s conclusions were misleading. The reanalysis used a subset with matched tumor and blood data, rather than every dataset in the original analysis. (LLM, conf=0.93)

  cites [244] source

In the paper

“However, they used a non-standard metric for tumor delivery defined as percent injected dose (%ID) in tumor = (AUCtumor/tend)*tumor mass.”

What the sources say

• Partly supported

  The Figure 1 caption (Perspective) defines delivery efficiency in % ID as tumour AUC divided by the study end-point time and multiplied by average tumour mass, matching the stated formula. The paper does not characterize that metric as non-standard; the Delivery efficiency and consequences section describes the underlying AUC method as commonly used in pharmacokinetic studies. (LLM, conf=0.86)

  cites [241] sourceExperimental — accuracy not yet measured

In the paper

“For the effective and safe delivery of drug combinations, the combination drugs should be well-solubilized in the polymeric micelle so that the amount of the excipient and injection volume can be minimized for parenteral injection [114, 188, 240].”

What the sources say

• Partly supported

  The Discussion (page unavailable) identifies efficient drug loading as critical and describes a stable, injectable two-drug micelle formulation using minimal polymer excipient. The Results (page unavailable) report high solubilization of both drugs. The paper does not state that this minimizes injection volume, so that part of the claim is unsupported by our copy. (LLM, conf=0.85)

  cites [114] sourceExperimental — accuracy not yet measured
• Partly supported

  The Introduction (page unavailable) says POx micelles solubilize poorly soluble drugs at high concentrations using much less excipient than current formulations, and links lower excipient exposure to reduced toxicity. The Discussion (page unavailable) reports high loading of both drugs. The paper does not state that this reduces injection volume for parenteral delivery, so that part of the claim is not directly supported. (LLM, conf=0.84)

  cites [188] sourceExperimental — accuracy not yet measured
• Partly supported

  The Introduction and Discussion (pages not provided) identify sufficient solubility for IV infusion and lower toxicity from avoiding conventional solubilizing vehicles as goals for micelle delivery. The Discussion also reports high drug loading for combinations. Our copy does not say that this minimizes excipient amount or injection volume for parenteral injection; the injection volume mentioned in Methods is for an analytical assay. (LLM, conf=0.86)

  cites [240] sourceExperimental — accuracy not yet measured

In the paper

“The conclusion was that the %ID in tumor was poorly correlated with the standard PK metrics which describe nanoparticle tumor delivery (AUCtumor/AUCblood ratio).”

What the sources say

• Supported

  The Discussion states that %ID in tumor was not related to the AUCtumor/AUCblood ratio, which it identifies as a standard PK metric describing the extent of tumor delivery. It reports that this held across the full dataset and all three nanoparticle subsets. (LLM, conf=0.95)

  cites [244] source

In the paper

“Also, according to Alves et al., POx micelles could solubilize many poorly soluble small molecules with high LC (Table 4) [116].”

What the sources say

• Partly supported

  The Results (Virtual screening of DrugBank and experimental evaluation; page not provided) report high loading capacity for several poorly soluble drugs, including podophyllotoxin and simvastatin. But the Introduction says POx micelles do not solubilize every poorly soluble drug equally well, and the Results describe many compounds with poor solubilization. The claim’s broad suggestion that many such molecules achieve high loading capacity overstates the reported findings. (LLM, conf=0.83)

  cites [116] sourceExperimental — accuracy not yet measured

In the paper

“They demonstrated that both doxorubicin (DOXIL® and Sun Pharma’s formulation) and paclitaxel (Abraxane® and Samyang’s Genexol® PM) nanoformulations had comparable encapsulated/unencapsulated/unbound PK parameters.”

What the sources say

• Partly supported

  The Results (page not provided) describe the doxorubicin formulations’ encapsulated, unencapsulated, and unbound PK parameters as very similar, though some differed significantly. They also describe Abraxane and Genexol-PM’s unencapsulated and unbound parameters as very similar. The claim overreaches for encapsulated paclitaxel PK: encapsulated drug was not observed for Abraxane and was observed only at the earliest time point for Genexol-PM. (LLM, conf=0.88)

  cites [247] sourceExperimental — accuracy not yet measured

In the paper

“The Discher Lab used PEO-b-PCL block copolymers and have reported on the increased systemic circulation times of worm-like polymeric micelles compared to spherical micelles.”

What the sources say

• Supported

  The Methods identify PEG–polycaprolactone (PEO-b-PCL) as a block copolymer used to make the filomicelles. The Abstract reports that, in rodents, these filomicelles circulated about ten times longer than spherical counterparts of similar chemistry. (LLM, conf=0.93)

  cites [256] source

In the paper

“In contrast, resiquimod, an imidazoquinoline TLR 7/8 agonist, solubilized in POx block copolymer (PMeOx-b-PBuOx-b-PMeOx) micelles had a superior tumor inhibitory effect in a metastatic model of lung adenocarcinoma, relative to anti-PD1 immune checkpoint blockade therapy as well as platinum-based chemotherapy, which is the mainstay of treatment for NSCLC.”

What the sources say

• Supported

  The Results (Tumor inhibition study; page not available) report that resiquimod in POx micelles substantially suppressed tumor progression, while anti–PD-1 had a modest effect and platinum-based chemotherapy combined with chemosensitizers did not improve survival over control in the metastatic mouse model. The Discussion likewise says the resiquimod formulation outperformed anti–PD-1 therapy. (LLM, conf=0.92)

  cites [259] source

In the paper

“They reported that the overall AUC of the drugs in the tumor from worm-like micelles were higher than from spherical micelles.”

What the sources say

• Partly supported

  The Results (page unavailable) report higher tumor AUCs for both drugs with co-loaded C6CP/ETO micelles than with single-drug micelles or their mixture. But the paper describes the ETO-only micelles as worm-like, not spherical, and the Discussion says the specific drug-delivery benefit of the worm-like shape is uncertain. The claim overstates the comparison as worm-like versus spherical micelles. (LLM, conf=0.87)

  cites [114] sourceExperimental — accuracy not yet measured

In the paper

“When the micellar drug permeability into the tumor is much less than the plasma bound drug permeability (Scenario A), then changes in the micelle drug retention have little effect on the tumor AUC.”

What the sources say

• Supported

  The Results passage describing the PK model defines Scenario A as much lower tumor permeability for micellar drug than for serum-bound drug. It then reports that changing micellar drug retention has a negligible effect on tumor AUC in that scenario—less than 0.024% of the calculated AUC. (LLM, conf=0.95)

  cites [188] source

In the paper

“The work showed that the critical parameter was the micelle encapsulated drug permeability into the tumor effector compartment.”

What the sources say

• Supported

  The Results state that, for the model and assumptions used, micelle permeability to the tumor is the decisive parameter for drug distribution to the tumor compartment. The claim paraphrases that modeled finding; the paper calls it the “tumor compartment,” rather than an “effector compartment.” (LLM, conf=0.91)

  cites [188] source

In the paper

“However, when the micelle permeability is similar to or better than that of plasma bound drug (Scenario B), then the micelle retention has a major effect of the tumor AUC.”

What the sources say

• Partly supported

  The Results (page not provided) report that greater micelle retention strongly increases tumor drug accumulation in Scenario B, where micellar and serum-bound drug permeability are equal. The paper does not model or report the claim's additional condition that micelle permeability is better than that of serum-bound drug. (LLM, conf=0.86)

  cites [188] sourceExperimental — accuracy not yet measured

In the paper

“It should be pointed out that both Wan et al. [188] and Bulitta et al. [248] models relied on stability of the micelles and did not account for a situation where formulation could influence the unbound drug concentration, like in the case of equilibrium micelle binding.”

What the sources say

• Supported

  Judging the Wan et al. model only, the Discussion (page unavailable) explicitly says its simulation assumed stable micelles that did not disintegrate into unimers. The Results (page unavailable) describe drug transfer between micelles and a serum-bound compartment, but not a separate unbound-drug compartment or equilibrium binding model for unbound drug. (LLM, conf=0.86)

  cites [188] source
• ?Not checked — no full text of the sourcecites [248] source

In the paper

“The latest study highlighted that even the best combinations of the chemotherapeutic agents determined in vitro as having the most potent and highly synergistic effect against non-small cell lung cancer (NSCLC) cells may not be effective against the in vivo tumor even at the MTD of those combinations [259].”

What the sources say

• Partly supported

  The Results (Characterization of POx formulations; Tumor inhibition study, pages unavailable) identify two strongly synergistic in vitro combinations that did not improve survival in an orthotopic lung adenocarcinoma mouse model. But the Results (Estimation of MTD, page unavailable) call the doses used the highest tested, well-tolerated doses and establish them as no-observed-adverse-effect levels, not maximum tolerated doses. The MTD qualification is therefore unsupported. (LLM, conf=0.86)

  cites [259] sourceExperimental — accuracy not yet measured

In the paper

“Recently, a study from our lab showed the improved PK profile of the drug vismodegib when encapsulated in a POx micelle for treatment of a pediatric brain tumor – medulloblastoma [113].”

What the sources say

• Supported

  The Results section reports that POx-micelle vismodegib produced higher drug concentrations and tumor exposure than conventional vismodegib in medulloblastoma-bearing mice. It also reports reduced clearance and volume of distribution, supporting the claim of an improved pharmacokinetic profile. Page numbers were not supplied in the passages. (LLM, conf=0.93)

  cites [113] source

In the paper

“That is, stronger micelle retention leads to significantly increased tumor AUC (Figure 7).”

What the sources say

• Partly supported

  The Results passage discussing Table 4 and Figure 7 says stronger micelle retention markedly increases tumor drug accumulation when micellar and serum-bound drugs have comparable tumor permeability. It also says the effect on tumor AUC is negligible when micellar permeability is much lower. The citing sentence omits that condition. (LLM, conf=0.90)

  cites [188] sourceExperimental — accuracy not yet measured

In the paper

“The size of polymeric micelles currently in clinical trials are less than 100 nm [6, 7].”

What the sources say

• ?Not checked — no full text of the sourcecites [6] source
• Partly supported

  The Results (Preparation and characterisation of NK105; page unavailable) report an approximately 85 nm mean diameter for NK105, a polymeric micelle. The Discussion and introductory passage identify other micellar formulations in clinical trials, but give no sizes for them. The paper therefore does not establish that polymeric micelles in clinical trials are generally less than 100 nm. (LLM, conf=0.86)

  cites [7] sourceExperimental — accuracy not yet measured

In the paper

“This study suggested that the worm-shaped POx micelles co-loaded with two drugs (etoposide and hydrophobic cisplatin analog) have increased accumulation of the drugs into tumor compared to spherical micelles loaded with just one drug.”

What the sources say

• Partly supported

  The Results report higher tumor concentrations and tumor AUCs for both drugs in co-loaded POx micelles than in single-drug micelles. However, the Discussion says the single-drug cisplatin-prodrug micelles were spherical while the single-drug etoposide micelles were elongated; the claim inaccurately describes the single-drug comparators collectively as spherical. (LLM, conf=0.88)

  cites [114] sourceExperimental — accuracy not yet measured

In the paper

“For example, the Discher group was to our knowledge the first to report on drastic PK differences between spherical and worm-like polymeric micelles made from the same block copolymer [256].”

What the sources say

• Partly supported

  The Abstract (page unavailable) reports a drastic pharmacokinetic difference in rodents: filomicelles circulated about ten times longer than spherical counterparts of similar chemistry. However, the Methods (page unavailable) describe a filomicelle copolymer as related to—but compositionally different from—the one used in earlier vesicle studies. The copy does not establish a comparison of spherical and worm-like micelles made from the same block copolymer, or the claim that this group was first to report one. (LLM, conf=0.86)

  cites [256] sourceExperimental — accuracy not yet measured

In the paper

“The POx block copolymer (PMeOx-b-PBuOx-b-PMeOx) was employed to solubilize drug combinations in a single high-capacity vehicle (over 50 % wt. drug in dispersed phase).”

What the sources say

• Supported

  The Abstract identifies the P(MeOx-b-BuOx-b-MeOx) micelle system and reports co-formulation of two drugs in a single vehicle with over 50 wt% drug in the dispersed phase. The Results section likewise reports that the combined drug loading exceeded 50%. (LLM, conf=0.94)

  cites [114] source

In the paper

“Superior anti-tumor activity of combination therapy was confirmed in ovarian and breast cancer preclinical models.”

What the sources say

• Supported

  The Conclusion (page not provided) reports increased anti-tumor efficacy of the co-loaded formulations in breast and ovarian cancer models. The Results (page not provided) identify ovarian carcinoma xenograft and breast cancer orthotopic models used to evaluate that efficacy. (LLM, conf=0.93)

  cites [188] source